MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jac/dkaa152

Медицинская библиотека · The Journal of antimicrobial chemotherapy · 2020

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.

Avataneo Valeria, de Nicolò Amedeo, Cusato Jessica, Antonucci Miriam, Manca Alessandra, Palermiti Alice, Waitt Catriona, Walimbwa Stephen, Lamorde Mohammed, di Perri Giovanni, D'Avolio Antonio

СтатьяПоддержка исследования: вне правительства СШАВалидационное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, following IV administration, remdesivir is rapidly distributed into PBMCs and converted within 2 h to the active nucleoside triphosphate form, while GS-441524 is detectable in plasma for up to 24 h. Nevertheless, remdesivir pharmacokinetics and pharmacodynamics in humans are still unexplored, highlighting the need for a precise analytical method for remdesivir and GS-441524 quantification.

OBJECTIVES

The validation of a reliable UHPLC-MS/MS method for remdesivir and GS-441524 quantification in human plasma.

METHODS

Remdesivir and GS-441524 standards and quality controls were prepared in plasma from healthy donors. Sample preparation consisted of protein precipitation, followed by dilution and injection into the QSight 220 UHPLC-MS/MS system. Chromatographic separation was obtained through an Acquity HSS T3 1.8 μm, 2.1 × 50 mm column, with a gradient of water and acetonitrile with 0.05% formic acid. The method was validated using EMA and FDA guidelines.

RESULTS

Analyte stability has been evaluated and described in detail. The method successfully fulfilled the validation process and it was demonstrated that, when possible, sample thermal inactivation could be a good choice in order to improve biosafety.

CONCLUSIONS

This method represents a useful tool for studying remdesivir and GS-441524 clinical pharmacokinetics, particularly during the current COVID-19 outbreak.

Для цитирования: Avataneo Valeria, de Nicolò Amedeo, Cusato Jessica, Antonucci Miriam, Manca Alessandra, Palermiti Alice, Waitt Catriona, Walimbwa Stephen, Lamorde Mohammed, di Perri Giovanni, D'Avolio Antonio. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.. The Journal of antimicrobial chemotherapy. 2020. DOI: 10.1093/jac/dkaa152.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.